Advertisement

Topics

Latest "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Stories

02:53 EST 20th January 2017 | BioPortfolio

Here are the most relevant search results for "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" found in our extensive news archives from over 250 global news sources.

More Information about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine for you to read. Along with our medical data and news we also list autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Clinical Trials, which are updated daily. BioPortfolio also has a large database of autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Companies for you to search.

Showing "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Articles 1–25 of 13,000+

Extremely Relevant

Epstein–Barr virus: more than 50 years old and still providing surprises

This Timeline article describes the discovery of the Epstein–Barr virus and summarizes the key advances in the field that have led to our current understanding of the role this virus plays in a number of different lymphoid and epithelial malignancies.


Can Epstein-Barr Virus Increase Breast Cancer Risk?

Epstein-Barr Virus might increase the risk of breast cancer, according to experiments with cell lines and mouse xenografts that identified a potential mechanism for the suspected link.

Scientists uncover how common Epstein-Barr virus causes blood cancer in adults and children

Scientists at the University of Sussex, trying to uncover how the common Epstein-Barr virus causes blood cancer in adults and children, have discovered how the virus takes control of two genes involved in cancer development so it can switch them on or off.


Epstein-Barr virus-encoded miR-BART6-3p inhibits cancer cell metastasis and invasion by targeting long non-coding RNA LOC553103

Association of Epstein–Barr virus reactivation with the recovery of CD4/CD8 double-negative T lymphocytes after haploidentical hematopoietic stem cell transplantation

Eppstein Barr virus may promote breast cancer development

New research reveals that infection with the Epstein-Barr virus (EBV) may put some women at increased risk for developing breast cancer. The findings, published online in the July issue of the journal EBioMedicine, may have important implications for...

EBV-derived microRNAs silence immune alarm signals of the host cell

Epstein-Barr virus (EBV) prevents infected cells from being attacked by the immune system. The virus drives production of small molecules, so-called microRNAs, that suppress alarm signals sent out by the infected cell. Scientists at Helmholtz Zentrum München have elucidated this previously unknown mechanism.

Epstein-Barr virus-positive follicular lymphoma

Causing Cancer at (a Chromosome's) Arm's Length

Yes, the Epstein-Barr Virus is carcinogenic, but in an unexpected way. Read more...

How a common virus triggers blood cancer

Scientists trying to uncover how the common Epstein-Barr virus causes blood cancer in adults and children, have discovered how the virus takes control of two genes involved in cancer development so it can switch them on or off.

“Kissing Disease” Virus Promotes Malignant Breast Cancer Development

In our adolescent years, we would often snicker at other kids who were diagnosed with mononucleosis, as it was (and often still is) colloquial referred to as the “kissing disease.” However, in recent years mounting evidence has suggested that infection with Epstein-Barr virus (EBV) has become associated with various forms of cancer—which is certainly no laughing matter. Alarm...

Common virus triggers blood cancer

Scientists at the University of Sussex, trying to uncover how the common Epstein-Barr virus causes blood cancer in adults and children, have discovered how the virus takes control of two genes involved in cancer development so it can switch them on or...

Scientists reveal how a common virus triggers blood cancer

Scientists at the University of Sussex, trying to uncover how the common Epstein-Barr virus causes blood cancer in adults and children, have discovered how the virus takes control of two genes involved in cancer development so it can switch them on or off.

Medical News Today: What is Mono and Should I Worry About It?

Learn all about mono, a condition that is often caused by the Epstein-Barr virus. This article looks at the symptoms, causes, treatment, and prevention.

Atara Bio Granted Access to Priority Medicines (PRIME) Regulatory Support for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL) for Treatment of EBV-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD)

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) and Commit...

How Epstein-Barr Virus Hijacks B Cells To Cause Blood Cancer

Scientists describe a mechanism by which EBV controls the expression of two genes, leading B cells to replicate out of control and avoid apoptosis.

Atara Bio Reaches Agreement with FDA on Design of Phase 3 Trials for its Lead Anti-Cancer Immunotherapy Program, Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, to Support Potential Approval in Two Separate Indicati

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on the designs of two Phase 3 trials for ATA 129 intended to supp...

Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein–Barr virus-associated gastric cancer: the prognostic implications

Atara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in Europe for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, for the Treatment of EBV-Associated P

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that pursuant to parallel scientific advice from the European Medicines Agency’s (EMA’s) Scientific...

Glioblastoma Survival Linked to Insurance Status: Oncotherapy Network & Cancer Network

(MedPage Today) -- Also, Epstein-Barr Virus associated with breast cancer risk?

Aethlon Medical begins sepsis-related virus study

Aethlon Medical has started Sepsis-related virus study, focusing on cytomegalovirus, epstein-barr and herpes simplex viruses.

Cognate to make dendritic cell cancer vaccine in $2.2m deal with Astorias

Asterias Biotherapeutics has selected Cognate BioServices for the process development and manufacture of its autologous dendritic cell vaccine candidate, AST-VAC1.

Patient Ethnicity Differences in Epstein-Barr Virus and DLBCL Outcomes

As part of OncoTherapy Network’s coverage of the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH), held December 3–6 in San Diego, California, we spoke with Sean Tracy, MD, PhD, at the Mayo Clinic in Rochester, Minnesota.

Cognate to make dendritic cell cancer vaccine in $2.2m deal with Asterias

Asterias Biotherapeutics has selected Cognate BioServices for the process development and manufacture of its autologous dendritic cell vaccine candidate, AST-VAC1.

Highlighting Patient Ethnicity Differences in Epstein-Barr Virus and DLBCL Outcomes

As part of OncoTherapy Network’s coverage of the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH), held December 3–6 in San Diego, California, we spoke with Sean Tracy, MD, PhD, at the Mayo Clinic in Rochester, Minnesota.


Quick Search
Advertisement
 

News Quicklinks